No information is available on the clinical use of sunitinib during breastfeeding. Because sunitinib and its metabolite are over 90% bound to plasma proteins, the amount in milk is likely to be low. However, one of its metabolites has a half-life of up to 110 hours, and might accumulate in the infant. The manufacturer recommends that breastfeeding be discontinued during sunitinib therapy and for at least 4 weeks after the last dose.
关于舒尼替尼在母乳喂养期间的临床应用尚无可用信息。由于舒尼替尼及其代谢产物与血浆蛋白的结合率超过90%，乳汁中的含量可能较低。然而，其一种代谢产物的半衰期长达110小时，可能会在婴儿体内蓄积。制造商建议在舒尼替尼治疗期间及最后一剂后至少4周内停止母乳喂养。
